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Introduction: Epithelial-to-mesenchymal transition (EMT) promotes cell migration and is important in metastasis.
Cellular proliferation is often downregulated during EMT, and the reverse transition (MET) in metastases appears
to be required for restoration of proliferation in secondary tumors. We studied the interplay between EMT and
proliferation control by MYB in breast cancer cells.
Methods: MYB, ZEB1, and CDH1 expression levels were manipulated by lentiviral small-hairpin RNA (shRNA)-mediated
knockdown/overexpression, and verified with Western blotting, immunocytochemistry, and qRT-PCR. Proliferation was
assessed with bromodeoxyuridine pulse labeling and flow cytometry, and sulforhodamine B assays. EMT was induced
with epidermal growth factor for 9 days or by exposure to hypoxia (1% oxygen) for up to 5 days, and assessed with
qRT-PCR, cell morphology, and colony morphology. Protein expression in human breast cancers was assessed with
immunohistochemistry. ZEB1-MYB promoter binding and repression were determined with Chromatin Immunoprecipitation
Assay and a luciferase reporter assay, respectively. Student paired t tests, Mann–Whitney, and repeated measures
two-way ANOVA tests determined statistical significance (P < 0.05).
Results: Parental PMC42-ET cells displayed higher expression of ZEB1 and lower expression of MYB than did the
PMC42-LA epithelial variant. Knockdown of ZEB1 in PMC42-ET and MDA-MB-231 cells caused increased expression of
MYB and a transition to a more epithelial phenotype, which in PMC42-ET cells was coupled with increased proliferation.
Indeed, we observed an inverse relation between MYB and ZEB1 expression in two in vitro EMT cell models, in matched
human breast tumors and lymph node metastases, and in human breast cancer cell lines. Knockdown of MYB in
PMC42-LA cells (MYBsh-LA) led to morphologic changes and protein expression consistent with an EMT. ZEB1
expression was raised in MYBsh-LA cells and significantly repressed in MYB-overexpressing MDA-MB-231 cells, which
also showed reduced random migration and a shift from mesenchymal to epithelial colony morphology in two
dimensional monolayer cultures. Finally, we detected binding of ZEB1 to MYB promoter in PMC42-ET cells, and ZEB1
overexpression repressed MYB promoter activity.
Conclusions: This work identifies ZEB1 as a transcriptional repressor of MYB and suggests a reciprocal MYB-ZEB1
repressive relation, providing a mechanism through which proliferation and the epithelial phenotype may be
coordinately modulated in breast cancer cells.* Correspondence: rik@svi.edu.au
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Epithelial-to-mesenchymal transition (EMT), well descri-
bed in development [1], enables carcinoma cells to invade
local tissues and metastasize to distant sites [2]. EMT
causes cell-cell detachment and basement membrane deg-
radation, permitting cell migration aided by actin cytoskel-
etal rearrangements. EMT triggers myriad intracellular and
extracellular signals, which combine to generate motile
cells and provide protection against pro-death signals
from the host and anticancer therapies, on the journey to
secondary sites and while in the systemic circulation
(reviewed in [3]).
ZEB1 (zinc-finger E-box-binding homeobox 1) is a
dual zinc-finger, DNA-binding transcription factor, re-
cognizing bipartite E-boxes (CACCTG, CAGGTG) and/
or Z-boxes (CAGGTA) [4,5]. ZEB1 as with ZEB2, Snail1
and 2, Twist1 and 2, TCF3 and 4, FoxC2, Goosecoid,
KLF8 and Id1 orchestrate EMT transcriptional and mor-
phologic changes (reviewed in [6]). In EMT, ZEB1 is a
direct transcriptional repressor of E-cadherin [7] plakophi-
lin3 [8], Crumbs3, HUGL2, and Pals1 [9,10]. ZEB1 may
also promote metastasis, as shown in a xenograft mouse
model [10] and significantly higher ZEB1 expression is
seen in human breast cancer cell lines of the more mesen-
chymal/invasive basal B subgroup [11-13].
The transcription factor MYB is an oncogene in
human leukemias, and in epithelial cancers of the colon
and breast (reviewed in [14,15]). MYB promotes prolifer-
ation and inhibits differentiation [14]. We have shown
that MYB drives proliferation and suppresses apoptosis
and differentiation in estrogen receptor (ER)-positive
breast cancer cells in response to estrogen [16,17], and
that it is essential for mammary carcinogenesis in xeno-
graft and transgenic models [18].
Mutual regulatory relations have been defined for
MYB and ZEB1 in the hematopoietic system. MYB and
Ets-1 synergize to overcome transcriptional repression
of MYB by ZEB1 [19], and MYB has been shown to
regulate ZEB1 expression in the developing inner ear
[20]. Conversely, ZEB1 maintains tight regulatory con-
trol over MYB during T-cell differentiation [21]. How-
ever, the mechanism of this relation has not been
defined, and it has not been reported in a solid tumor
(cell) context.
A number of transcriptional repressors of CDH1 have
been demonstrated to impede cell-cycle progression
directly (reviewed in [22]). Colon cancer cells undergoing
an EMT at the invasive front coincide with the region
where ZEB1 is expressed [23] and display a downregula-
tion of proliferation [24]. Conversely, miR-200 family
members, which target ZEB mRNA for degradation [4],
have been shown to have a pro-proliferative role [25,26],
thus promoting the growth of breast cancer cell metasta-
ses [27]. However, a pro-proliferative role has also beendescribed for ZEB1, because in some contexts, it represses
the cell-cycle inhibitors p21 and p73 [28,29]. The current
study sought to determine the ZEB1/MYB/proliferation
interplay in the epidermal growth factor (EGF)-responsive
PMC42 model of breast cancer EMT.
The PMC42 model system [6] comprises the parental
cell line PMC42-ET (ET) and its more epithelial variant
PMC42-LA (LA). Both lines exhibit EMT in response to
EGF [30,31], with marked differences in EMT-marker
protein expression and arrangement [32]. Here we have
identified an inverse relation between ZEB1 and MYB
throughout these cell states, and also in the breast
cancer cell lines MDA-MB-231 and MDA-MB-468. We
showed that ZEB1 is a key player in promoting the
mesenchymal phenotype and regulating the proliferative
rate in ET cells through the direct transcriptional repres-
sion of MYB. Release of MYB repression promotes an
epithelial phenotype, or MET, in which proliferation is
restored. MYB and CDH1 gene expression were found
to correlate in human breast cancer cell lines and in
primary human breast tumors and metastases. Collec-
tively our data link the transcriptional regulation of
MYB by ZEB1 to the proliferative state of cells during
EMT-MET in breast cancer, and also indicate a contri-
bution of MYB to the epithelial phenotype.
Methods
Cell culture
PMC42-ET (ET) cells were derived from a breast can-
cer pleural effusion by Dr. Robert Whitehead, Ludwig
Institute for Cancer Research, Melbourne, Australia,
with appropriate institutional ethics clearance (Institu-
tional Review Board of the Peter MacCallum Hospital,
Melbourne) and informed consent of the patient. The
PMC42-LA (LA) subline was derived further from the
parental PMC42- ET cells by Dr. Leigh Ackland, Deakin
University, Melbourne, Australia [30,33-35]. These cells,
and all modified (shRNA) derivatives, were maintained at
37°C, 5% CO2 in RPMI1640 containing 10% fetal calf
serum (FCS; Thermo Fisher Scientific, Waltham, MA,
USA). T47D cells and MCF-7 cells (used in EGF and
hypoxic assays) were obtained from the American Type
Culture Collection (ATCC, Rockville, MD, USA). MCF-7
cells used for constitutive MYB expression were provided
by the Michigan Cancer Foundation to the Garvan Insti-
tute, Sydney, Australia. MDA-MB-468 cells originally
from the ATCC were transferred from the Lombardi
Cancer Center, Washington, DC, USA. All were main-
tained in Dulbecco Modified Eagle Medium (DMEM;
Thermo Fisher Scientific). For induction of EMT via
hypoxia, MDA-MB-468 cells were cultured at 1% O2, 5%
CO2 in a hypoxia workstation (INVIVO2400; Ruskinn
Technology Ltd, Bridgend, UK). For EGF-induced EMT,
approximately 30% confluent LA cells were treated with
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USA) at 10 ng/ml. After trialing incubation times and
concentrations we concluded that treatment of PMC42-
LA cells with EGF for 9 days generated a robust and
reproducible EMT (as indicated by QRT-PCR and
morphology; data not shown). Three dimensional (3D)
culture conditions were created by using the Matrigel
“on-top” assay [36].Creation of modified cell lines
Generation of shRNA-expressing ET, LA, MDA-MB-
468, or MDA-MB-231 cells was achieved by using the
Lenti-X HTX packaging system (Clonetech Laboratories,
Mountain View, CA, USA) and following the manufac-
turer’s instructions; shRNA sequences (Table 1) were
encoded within a GFP-expressing lentiviral vector
(pGIPZ; Thermo Scientific Open Biosystems, distributed
by Millenium Science, Surrey Hills, VIC, Australia). Suc-
cessfully transduced cells were selected by cell sorting
for GFP; thus a transduced pool rather than individual
clones was used in these studies. Stable MYBs express-
ing MDA-MB-231 and MCF-7 cells were generated by
lentiviral transduction, whereby MYB and green fluo-
rescent protein (GFP) were co-expressed by using the
pLV411G vector [37,38]. Successfully transduced cells
were selected by cell sorting for GFP.Immunofluorescence microscopy, multiplex tandem
polymerase chain reaction (MT-PCR), and quantitative
real-time PCR (QRT-PCR)
These were performed as previously described [39]. Details
of antibodies and QRT-PCR primers used are provided in
Tables 2 and 3, respectively. Gene-symbol abbreviations
used in the current study are shown in Table 4.Table 1 Details of shRNAs used in current study
Gene Clone ID
Zeb1sh var1 V2LHS_116662
Zeb1sh var2 V2LHS_116659
Zeb1sh var3 V2LHS_116663
Zeb1sh var4 V2LHS_226625
MYBsh var1 V2LHS_36797
MYBsh var2 V2LHS_36795
CDH1sh A V2LHS_14834
CDH1sh B V2LHS_14838
CDH1 shC V2LHS_14837
CDH1 sh D V2LHS_243170
Zeb1 shRNAs were purchased directly from Open Biosystems; MYB and
E-cadherin shRNAs were provided by the Victorian Centre for Functional
Genomics (VCFG), Peter MacCallum Cancer Centre.Immunobead-negative selection and FACS analysis for
EpCAM
LA, SCRsh-ET (SCR, scrambled control shRNA) and
ZEB1sh-ET were trypsinized and counted, and approxi-
mately 106 cells were added to 20 μl of beads (Collection
Epithelial Enrich, Dynal (Invitrogen) to a final volume of
5 ml and incubated at 4°C with rotation for 2 hours. The
bead-cell mixture was then placed in a DynaMag-15
magnet (Invitrogen) to separate beads from solution.
The number of unbound cells was then determined and
represented as a proportion of the original population.
Anti-human EpCAM and CDH1 antibodies (Biolegend,
San Diego, CA, USA) were used for fluorescence-activated
cell sorting (FACS). Cells were trypsinized and counted,
and approximately 106 cells in PBS were incubated with
20 μl of antibody for 30 minutes in the dark at 4°C. Cells
were then washed twice with 1 ml of phosphate-buffered
saline (PBS) and resuspended in 300 μl of PBS, transferred
to a 5-ml polystyrene tube and fluorescence measured by
using the LSR Fortessa II (BD Biosciences). Data were
analyzed by using FlowJo Software (version 7.6.4).
BrdU (bromodeoxyuridine) pulse labeling and flow
cytometry, sulforhodamine B (SRB) colorimetric assay,
Western blotting
These were performed as previously described [40-43].
Clonogenic assay and colony morphology analysis
Cells were trypsinized to a single-cell suspension, and
2,000 cells plated in 10 ml of media in an 8-cm-diameter
culture dish. After 9 to 10 days, the cells were fixed in
10% neutral buffered formalin, stained with crystal violet
(0.5% wt/vol), and washed with PBS. Plates were dried
overnight face down. Images were taken of each plate by
using the VersaDoc system, and a ‘‘thresholded” image
was generated by the imaging program Image J when
particular upper and lower pixel-intensity values were
set (in the case of the images in Additional file 1: Figure
S1C, and Additional file 2: Figure S2B, it was set to auto-
matically detect the threshold, usually at pixel intensities
between 129 and 255). This effectively segmented the
image into colonies and background. Colonies were then
counted by using this imaging program. Colony mor-
phology was assessed by counting a minimum of 100
colonies/plate and classifying them based on the phe-
notypes displayed in Figure 1B(ii).
Monolayer wound-healing assay
MYB-transfected MDA-MB-231 cells and sh-MYB-
knocked-down LA cells were plated in a 24-well plate
set up in triplicate and incubated at 37°C for 24 hours to
allow the formation of a confluent monolayer. The cells
were then wounded by using a P200 pipette tip. The
wounded monolayers were washed with complete media
Table 2 Antibodies used for IF, ICC, and IHC
Primary antibody Species Source
Snail1 Rat Cell Signaling Technology, Beverly, MA, USA (cat. no. 4719)
Snail2 Rabbit Abcam, Cambridge, UK (cat. no. ab27568)
Zeb1 Goat Santa Cruz Biotechnology, Santa Cruz, CA, USA (cat. no. sc-10572)
Vimentin Mouse DAKO, Campbellfield, VIC (cat. no. H 7095)
E-cadherin Rabbit Abcam, Cambridge, UK (cat. no. ab40772)
E-cadherin Mouse BDT (cat. no. 612130)
MYB Mouse Millipore, Billerica, MA, USA (cat. no. 05–175)
α-pan actin Mouse Abcam, Cambridge, UK (cat. no. ab75373)
ER-α Mouse DAKO, Campbellfield, VIC (cat. no. M 7047)
Cytokeratin Mouse DAKO, Campbellfield, VIC (cat. no. M 0821)
CT3 MYB w CT5 Mouse Synthesized in lab of Prof. Gonda
Secondary antibody Species Source
Anti-mouse Alexa 488 Goat Invitrogen, Camarillo, CA, USA (cat. no. A-11011)
Anti-mouse biotin Rabbit DAKO, Campbellfield, VIC (cat. no. E0354)
Anti-goat biotin Rabbit Vector Laboratories, Burlingame, CA, USA (cat. no. BA-5000)
Anti-rabbit biotin Swine DAKO, Campbellfield, VIC (cat. no. E0431)
Tertiary label Source
Streptavidin/HRP DAKO, Campbellfield, VIC (cat. no. P0397)
DAPI (4′,6-Diam idino-2-phenylindole, dihydrochloride)
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taken at 0, 24, and 48 hours. Wound areas at each time
point were analyzed and quantitated by using ImageJ
software.
Transwell-migration assay
Cells were trypsinized to form a single-cell suspension
and resuspended into invasion medium (serum-free
RPMI supplemented with 0.1% BSA). Cell counts and
viability were estimated by using the Countess Auto-
mated Cell Counter (Invitrogen). Then 1 × 105 cells in
100 μl of invasion medium were added into the upperTable 3 Primers used in QRT-PCR
Gene Forward primer sequence
L32 GATCTTGATGCCCAACATTGGTTATG
Snail1 CCAGACCCACTCAGATGTCAAGAA
Snail2 CCCAATGGCCTCTCTCCTCTTT
Twist1 CTAGAGACTCTGGAGCTGGATAACT
Zeb1 GTTACCAGGGAGGAGCAGTGAAA
MYB CAGGAAGGTTATCTGCAGGAGTCTT
E-cadherin GCCCTGCCAATCCCGATGAAA
Vimentin GCTTCAGAGAGAGGAAGCCGAAAA
ERα GGAGCACCCAGGGAAGCTACTGTTT
MKI67 GTAGGTGAGGGCAAAGGCACGAAA
Primers for ChIP AGCAGGTGGGAATTCGTTCCcompartment of each migration chamber (6.5-mm
Transwell with 8.0-μm pore polycarbonate membrane
insert, Corning). The lower chamber contained 600 μl of
chemoattractant medium (RPMI supplemented with
10% FBS and 0.1% BSA). The plates were then incubated
at 37°C for 4 hours. The membranes were then washed
twice in 1× PBS, fixed in cold methanol for 2 minutes,
stained with Diff-Quick (1 minute with eosin, followed
by 1 minute with buffered thiazole), and washed with
water to remove any excess stains. The nonmigrated
cells that remained on the upper surface of the mem-
brane were removed by carefully wiping with a cottonReverse primer sequence
GCACTTCCAGCTCCTTGACG
GGCAGAGGACACAGAACCAGAAAA
CATCGCAGTGCAGCTGCTTATGTTT
AAAAA CGACCTCTTGAGAATGCATGCATGAAAAA
GACAGCAGTGTCTTGTTGTTGTAGAAA
CAAAA CTATAGGCGGAGCCTGAGCAAAA
GGGGTCAGTATCAGCCGCT
CCGTGAGGTCAGGCTTGGAAA
GATCTCCACCATGCCCTCTACACATTTT
CTTCCGCTTTGCAGGTTGCTTAAA
CCAACGTCCGGATACATTTC
Table 4 Definition of gene symbols and names used in
current study
Gene symbol Detailed name
CA9 Carbonic anhydrase IX
CD24 CD24 molecule (Indian blood group)
CD44 CD24 molecule (Indian blood group)
CDH1 Cadherin 1, type 1, E-cadherin (epithelial)
CDH13 Cadherin 13, H-cadherin (heart)
CDH2 Cadherin 2, type 1, N-cadherin (neuronal)
CDH5 Cadherin 5, type 2 (vascular endothelium)
CTGF Connective tissue growth factor
CYR61 Cysteine-rich, angiogenic inducer, 61
E12/E47 Transcription factor 3 (E2A immunoglobulin
enhancer binding factors E12/E47)
EPCAM Epithelial cell adhesion molecule
ESR1 Estrogen receptor 1
FOXC2 Forkhead box C2 (MFH-1, mesenchyme forkhead 1)
GSC Goosecoid homeobox
KRT7 Keratin 7
MKI67 Antigen identified by monoclonal antibody Ki-67
MMP1 Matrix metallopeptidase 1 (interstitial collagenase)
MMP13 Matrix metallopeptidase 13 (collagenase 3)
MMP14 Matrix metallopeptidase 14 (membrane-inserted)
MMP2 Matrix metallopeptidase 2 (gelatinase A, 72-kDa
gelatinase, 72-kDa type IV collagenase)
MMP9 Matrix metallopeptidase 9 (gelatinase B, 92-kDa
gelatinase, 92-kDa type IV collagenase)
MYB V-myb myeloblastosis viral oncogene homolog (avian)
PAX2 Paired box 2
PAX6 Paired box 6
PLAU Plasminogen activator, urokinase
SNAI1 Snail homolog 1 (Drosophila)
SNAI2 Snail homolog 2 (Drosophila)
TWIST1 Twist homolog 1 (Drosophila)
VIM Vimentin
ZEB1 Zinc-finger E-box binding homeobox 1
ZEB2 Zinc-finger E-box binding homeobox 2
Annotation according to the National Center for Biotechnology Information,
U.S. National.
Library of Medicine online Gene search.
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quently mounted on slides. Five random high-power
fields per membrane were imaged and counted by using
ImageJ software.
Live cell-migration analyses
Live-cell imaging was performed on cells plated at 1 × 105
cells/dish in 3-cm TC glass-bottom dishes (FluoroDish;
World Precision Instruments, Inc., Sarasota, FL, USA) byusing magnification × 10 phase-contrast objective on
an Olympus IX70 microscope attached to a Spot
Monochrome camera (2.1.1). Images were acquired
for 120 to 150 frames at one frame per 2 minutes, by
using Image-Pro Plus 4.5 (MediaCybernetics, Silver
Spring, MD, USA). Analysis was via Image-Pro–Analyser
6.1 (MediaCybernetics).
Immunocytochemistry
Antibodies are detailed in Table 2. Cells were cultured on
Superfrost plus slides (Thermo Scientific, Scoresby, VIC,
Australia) overnight then fixed in ice-cold methanol for
20 minutes at −20°C. After 3× PBS 5-minute washes,
slides were immunostained by following the protocol de-
scribed in the Immunohistochemistry section later.
Human breast primary and matched sentinel lymph-node
sections
Formalin-fixed, paraffin-embedded surgical specimens
were obtained from St. Vincent’s Pathology, Melbourne,
with approval of the St. Vincent’s Hospital Human
Research Ethics Committee (006–09). Specific patient
consent was not required for this study, on the basis that
(i) the tissues were collected by the hospital for hospital
procedures, (ii) individual patients could not be iden-
tified, and (iii) this project did not affect tissue donors’
disease or treatment.
Immunohistochemistry
Antibodies are detailed in Table 2. Paraffin-embedded
blocks were sectioned, mounted on Superfrost plus
slides, de-waxed, and then brought to water. Slides were
incubated in primary antibody overnight at 4°C (all anti-
bodies were diluted in 0.1% bovine serum albumin
(BSA)/PBS), washed in 0.1% Tween20/1 × PBS, and then
incubated with a biotinylated secondary antibody. Slides
were then washed in 1 × PBS and incubated with strepta-
vidin-linked HRP tertiary antibody. Staining was visualized
with peroxidase-sensitive Sigmafast 3,3′-diaminobenzi-
dine tablets (DAB; Sigma), resuspended to 0.5 mg/ml
in 50 mM Tris, pH 7.6, containing 150 μl H2O2. Slides
were counterstained with Mayer’s hematoxylin solution
(Amber Scientific, Midvale, WA) and mounted in DPX
(BDH, Poole, England).
Chromatin immunoprecipitation (ChIP) assay
SCRsh-ET and ZEB1sh-ET cells were grown in T175
flasks to 70% to 80% confluence (approximately 2 to ×
107 cells). Cells were washed 3 times with PBS and
incubated 20 minutes at room temperature with 1%
formaldehyde. Cross-linking was stopped by the addition
of 0.1M glycine for 5 minutes at room temperature.
Cells were washed 3 times with PBS and resuspended in
1.0 ml of lysis buffer (50 mM Tris–HCl, pH 8.1, 1.0%
0.5
0.22
Figure 1 Manipulation of MYB expression influences epithelial/mesenchymal gene expression and clonal morphology. (A) Stable
knockdown of MYB in LA cells by shRNA led to mesenchymal gene-expression changes (i) Analysis of MYB expression reduction (notation on
graph bar indicates level of fold reduction; n = 3, error bars represent SEM, *, significance set at P < 0.05, Student paired t test) and (ii) further
validation of MYB knockdown and analysis of EMT markers CDH1 and VIM with Western blot. (B) Colony morphology was significantly altered in
MYB-overexpressing MDA-MB-231 cells. (i) MYB overexpression validated by Western blotting; (ii) examples of the three different colony phenotypes
ranging from more-epithelial/compacted (phenotype 1) to most-mesenchymal/scattered (phenotype 3), and representative images of colonies seen in
vector control- or MYB-transfected MDA-MB-231 cells, and (iii) increased epithelial (phenotype 1) and decreased mesenchymal (phenotypes 2, 3) seen
after MYB transfection of MDA-MB-231 cells (n = 2; ANOVA. **P < 0.005; ****P < 0.0001).
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Chromatin was sonicated (Bioruptor UCD-200, Diagenode)
for 10 cycles of 20-second sonication by using 40%
efficiency with 2-minute incubation at 4°C between
the sonication steps to achieve an average chromatin
length of 1 kbp. Chromatin extracts were centrifuged
for 14,000 rpm for 30 minutes at 4°C, and the supernatant
was diluted 1:10 with IP dilution buffer (20 mM Tris–HCl,
pH 8.1, 1.0% Triton X-100, 2.0 mM EDTA, 150 mM NaCl).Diluted chromatin extracts were pre-cleared with Pro-
teinA/G-agarose (Santa Cruz) for 1 hour at 4°C and
subsequently used for immunoprecipitation with 2 μg
of ZEB1 antibody (E-20; Santa Cruz) or 2 μg of control
anti-goat IgG antibody overnight at 4°C. Immunoprecipi-
tants were collected by the addition of 100 μl ProteinA/G-
agarose (Santa Cruz) precoated with BSA and salmon
sperm DNA. After incubation for 1 hour at 4°C, the agar-
ose was pelleted and washed for 15 minutes with each of
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pH 8.1, 0.1% SDS, 1.0% Triton X-100, 2.0 mM EDTA, and
150 mM NaCl), high-salt buffer (20 mM Tris–HCl,
pH 8.1, 0.1% SDS, 1.0% Triton X-100, 2.0 mM EDTA,
500 mM NaCl), LiCl buffer (10 mM Tris HCl, pH 8.1,
1 mM EDTA, 1.0% deoxycholate, 1.0% NP-40, 0.25M
LiCl), followed by three washes in 1× TE. Complexes
were eluted with 500 μl elution buffer (1.0% SDS, 0.1M
NaHCO3). Eluates were adjusted with NaCl (0.2M) and
cross-links reversed by heating the samples at 65°C
overnight. Eluates were adjusted with EDTA (10 mM) and
50 mM Tris HCl, pH 6.5) and subsequently treated with
Proteinase K (2 μl of 10 mg/ml) for 1 hour at 45°C. DNA
was recovered by phenol/chloroform/isoamyl alcohol
extraction and ethanol precipitation and resuspended in
50 μl 1× TE. Samples were quantified with SYBR-green
real-time PCR analysis (Applied Biosystems). Details of
primers used for Q-PCR analysis are found in Table 3.
Results were expressed as the percentage of total DNA
immunoprecipitated with ZEB1 antibody or control anti-
goat IgG relative to unprecipitated input samples that
were used as reference for all QRT-PCR reactions.
Plasmid DNA, transfection, and reporter gene assay
pMYB prom + intron1 CAT (chloramphenicol acetyl-
transferase) and pMYB prom CAT were described in a
previous study [44], and pMYB prom + intron1 CAT b
(used in this study) was in the previous study named 5′-3′.
In pMYB prom + intron1 CAT construct, the promo-
ter, exon 1, and intron 1 sequences of MYB gene
were cloned upstream of the CAT. Both sets of E/Z
boxes identified in Figure 2A were included in this
construct. pMYB prom + intron1 CAT construct b was
a shortened version, containing only the first set of
Z/E boxes upstream of CAT. pMYB prom contained
the promoter region only, encompassing only the first
Z-box. This was then mutated by using the Quick-
Change Site-Directed Mutagenesis Kit (Stratagene/In-
tegrated Sciences), such that CAGGTA was mutated
to GTGGTA, and named MYB prom MUT CAT.
Expression of exogenous ZEB1 from the expression
construct (pcDNA3.1-ZEB1) [45] was confirmed with
Western blot by using a goat anti-ZEB1 antibody C-
20, sc-10570; Santa Cruz). A β-galactosidase expres-
sion vector was used as an internal control in the
reporter assay. Approximately 7 μg of total plasmid DNA
was transfected into HEK293T cells by using Fugene HD.
In brief, 1.6 × 106 cells/T25 tissue-culture flask was
seeded, and transfections were carried out according to
manufacturer protocol. After 72 hours of transfection,
cells were lyzed by using 1 ml of lysis buffer/T25 flask,
and 200 μl of extract was used to quantitate CAT reporter
gene activity by using a CAT-ELISA enzyme immunoassay
kit (Roche Applied Science, Castle Hill, NSW, Australia).Statistical analyses
Student paired t tests were performed by using Microsoft
Excel version 2003 (18.8335.8333) SP3. Mann–Whitney
and analysis of variance (ANOVA) tests were performed
by using Graph Pad Prism (GraphPad Software, San
Diego, CA, USA). Where “n” is used (as in n = 3), this
refers to the number of independent, biologic repli-
cate experiments performed.
Results
Gene-expression analysis in the PMC42 EMT model
The parental ET cells display mesenchymal characteris-
tics compared with the more-epithelial LA derivative,
providing a unique opportunity to investigate the epithe-
lial –mesenchymal axis in isogenic breast cancer cell
lines [6,31,32]. In investigating the cellular localization
and expression of three significant EMT regulators,
SNAI1, SNAI2, and ZEB1 [5] between LA and ET cells,
ZEB1 nuclear staining and mRNA abundance had the
greatest differential and favored the ET cells (Figure 3A,
B). By contrast, MYB expression was significantly higher
in LA cells (Figure 3B). ET cells also expressed lower
levels of E-cadherin (CDH1) and higher levels of vimen-
tin (VIM) than did LA cells (Figure 3B), as previously
shown immunocytochemically [32]. Somewhat surpris-
ingly, lower levels of Twist1 (TWIST1) were seen in ET
cells compared with LA (Figure 3B).
ZEB1sh-ET cells are epithelially shifted, express higher
MYB, and are more proliferative
We previously showed that transient knockdown of
ZEB1 with siRNA caused re-expression of CDH1 in ET
cells [32]. Here we established stable ZEB1 knocked-
down ET cell lines with four shRNA variants and a”:
scrambled” nontargeting hairpin control (SCRsh-ET).
The level of ZEB1 knockdown was proportional to
CDH1 reexpression (Figure 4A, parts i, ii; Further cha-
racterization of ZEB1sh-ET cells is shown in Additional
file 3). Variant number 4 (hereafter designated ZEB1sh-
ET) displayed the greatest ZEB1 knockdown and com-
mensurate CDH1 protein reexpression. Examination of
the expression of EMT-related genes revealed that ZEB1
knockdown in ET cells caused MET-like gene-expression
changes, including increased expression of CDH1 and
CD24, and reduced expression of MMP1, a known target
of ZEB1 for induction [46] (Figure 4A, part iii). Further
proepithelial changes due to ZEB1 knockdown are
shown in Additional files 3 and 4. These experiments
suggested that suppression of ZEB1 caused gene-expres-
sion changes similar to the paired LA-versus-ET model
of MET. Similarly, expression of MYB protein (Figure 4B)
and mRNA (Additional file 3D) was higher in ZEB1sh-ET
cells. Pax-2 was also increased (Figure 4A, part iii), but no
change was seen in a variety of other markers, including
Figure 2 Regulation of the MYB promoter by ZEB1. (A) (i) Outline of several CAT reporter constructs containing MYB promoter and intron 1
sequences with various numbers of E and Z boxes, which were used in the CAT ELISA assay. (ii) Western blot of HEK 293 cells transfected with
various amounts of pcDNA3.1-ZEB1 expression construct, as surrogate validation of ZEB1 expression in the CAT ELISA assay. (iii) Results of a CAT
ELISA assay, “+ZEB1” expressed as fold change from each individual CAT reporter alone, n = 1; error bars represent standard deviation. (B) Scheme
of the MYB gene indicating (black bars) the position of E-boxes and Z-boxes, sites at which ZEB1 may bind [4]. Red bars indicate QRT-PCR primers
used in the ChIP assay. (C) ChIP analysis of SCRsh-ET and ZEB1sh-ET cells using anti-ZEB1 (E20; Santa Cruz) and control anti-goat IgG. The graph
depicts the enrichment of PCR-amplified immunoprecipitated DNA expressed as a percentage of total DNA immunoprecipitated with ZEB1
antibody or control anti-goat IgG relative to unprecipitated input sample. Data are representative of three independent assays (error bars represent SD).
Additional data are shown in Additional file 9: Figure S9B.
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MMP13, and MMP14 (Additional file 1A).
ZEB1 knockdown in ET cells was associated with
an increased rate of proliferation, as shown by BrdU
(bromodeoxyuridine) pulse labeling and flow cytometry(Figure 4C, part i). Over the 15-hour period after arrest,
we observed a significantly higher proportion of ZEB1sh-ET
cells in S phase compared with SCRsh-ET cells, indicative of
an increase in proliferation. The ZEB1sh-ET cells also proli-
ferated faster than SCRsh-ET cells in the sulforodamine B
Figure 3 MET/EMT cell states in the LA/ET breast cancer cell system. (A) Immunofluorescence for CDH1-repressor genes SNAI1, SNAI2, and
ZEB1 (as indicated with green fluorescence (488) and nuclei stained with 4′,6-diamidino-2-phenylindole (DAPI), magnification 600×, scale bar,
50 μm; and (B) their expression along with other EMT-related genes, and MYB. Fold gene expression (for all QRT-PCR in this article, this is first
corrected to housekeeping ribosomal protein L32; MYB, SNAI1, SNAI2, and ZEB1 are QRT-PCR data; all others are MT-PCR first corrected to the
housekeeping genes L32, GUSB, and NONO) is shown, relative to PMC42-LA, which has been set to 1. Data shown are an average of three
independent biologic replicates, error bars represent SEM. Student paired t test was used to determine significance; P < 0.05.
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shown in Additional file 1B). ZEB1sh-ET cells also
grew larger colonies from a single cell compared withthe SCRsh-ET cells (Additional file 1C), an increase that
was negated when MYB was knocked down (Additional
file 2A and B). Fewer colonies were seen after ZEB1
Figure 4 ZEB1sh-ET cells are more epithelial, express higher MYB, and are more proliferative than SCRsh-ET controls. (A) (i) Western
blotting for ZEB1 and CDH1 in PMC42-ET cells transfected with shRNA variants 1 to 4; (ii) bar graph of band intensity of the Western blot shown
in (i). (iii) Expression (MT-PCR) of EMT-related genes, ZEB1sh-ET relative to SCRsh-ET; fold expression shown. Data shown are the average of four
independent biologic replicates; Student paired t test was used to determine significance (*), set at P < 0.05; error bars represent SEM. The
expression of other EMT-related genes not shown in this figure is shown in Additional file 1, part A. (B) ZEB1sh-ET express higher MYB protein
and mRNA (Additional file 3D) and are more proliferative (C). (i) Percentage of ZEB1sh-ET cells in S phase as determined by BrdU staining after
release from mitotic arrest with nocodazole; (ii) Growth rate as shown by the SRB growth assay. Results shown (C, part i) are from three independent
experiments; error bars represent SEM, and the repeated-measures two-way ANOVA statistical test was used to determine significance, *P < 0.05.
Result shown in (ii) is one representative SRB assay, of a total of three, all of which were found to be statistically significant by the repeated-measures
two-way ANOVA statistical test. Further replicates are found in Additional file 1B. (D) ZEB1 knockdown in MDA-MB-231 breast cancer cells: (i)
characterization of ZEB1 knockdown (shRNA) MDA-MB-231 cells by QRT-PCR; (ii) immunocytochemistry showing that ZEB1 knockdown results in
reexpression of E-cadherin at the cell membrane, and MYB nuclear reexpression; magnification, 400×, scale bar, 50 μm.
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models of regulation including survival, apoptosis, anoi-
kis, all of which have been linked to EMT. In MDA-
MB-231 cells, ZEB1 knockdown also led to increased
CDH1 at the cell membrane and MYB expression
(Figure 4D, part i), the latter being shown to be nuclear
(Figure 4D, part ii). Consistent with previous work [10],
we observed that these ZEB1-knockdown cells, when
plated in 3D, exhibited diminished sprouting and retarded
wound closure (data not shown).
MYB and ZEB1 expression are inversely correlated in
various in vivo and in vitro biologic settings
We examined the ZEB1/MYB relation more broadly in
EMT and in human breast tumors. Hypoxia has been
reported to induce EMT in MDA-MB-468 cells [48,49].
In a time course of 5 days of hypoxia, only ZEB1 was
significantly induced of the eight CDH1 repressor genes
examined (Figure 5A, part i, immunocytochemistry for
E-cadherin and vimentin: Additional file 5A). This was
observed at day 5, when MYB expression was also sig-
nificantly reduced. MYB repression also accompanied
hypoxia-induced EMT-like expression changes in MCF-
7 cells (see Additional file 6A).
After 9-day treatment of PMC42-LA cells with 10 ng/ml
EGF, VIM and ZEB1 expression were upregulated, and
MYB expression was downregulated (Figure 5A, part ii,
morphologic changes: Additional file 5B). EGF-induced
EMT also led to the repression of MYB in the cell line
T47D (Additional file 6B).
Given that tumor aggressiveness has been linked with
EMT ([51], reviewed in [52]) we examined the expres-
sion of MYB in a publically available microarray dataset
series of human breast tumors [50] and observed that
MYB expression was generally high in Luminal A and
Normal-like tumors but dramatically lower in Basal and
Her2 + tumors (Figure 5B). This finding is consistent
with previous work that also showed that MYB expres-
sion in luminal tumors correlated with a good prognosis
[53]. Analysis of publically available expression data [13]
from 51 human breast cancer cell lines that clustered
into Luminal, BasalA, and BasalB subgroups [6,11]
also revealed significantly higher MYB expression in
Luminal and Basal A subgroups compared with Basal B
(Additional file 5C). This pattern was the inverse to that
of ZEB1, but correlated with CDH1.
In our study, serial sections from paraffin-embedded
matched tissue sets of primary tumors and involved lymph
nodes from 11 individual patients were immunostained
with the various markers listed in Figure 5C, part i. Histo-
logic examination of another primary tumor-lymph node
set from this group of 11 is shown in Additional file 5D.
MYB was found to be nuclear and generally tumoral, and
associated with epithelial markers CDH1 and cytokeratinalong with ERα, particularly in primary tumor samples
(invasive ductal breast carcinomas). MYB and associated
markers were inversely expressed with regard to VIM.
This is further supported by a positive correlation of MYB
and CDH1 in breast cancer bone metastases, with both
markers staining inversely to VIM (Figure 5C, part ii).The manipulation of MYB expression influences epithelial
versus mesenchymal state
Given that ZEB1 knockdown led to MYB reexpression and
epithelialization, we investigated whether these changes were
causally linked. Knockdown of MYB mRNA (Figure 1A, i)
and protein (Figure 1A, ii) in the more-epithelial LA
cells (MYBsh-LA) reduced CDH1 and induced VIM
protein expression (Figure 1A, ii). To investigate this fur-
ther, we created a stable MYB-overexpressing MDA-MB-
231 cell line (Figure 1B, part i), and found a shift from
mesenchymal, scattered colonies to more-compact epithe-
lial colonies in these cells compared with vector control
cells, when plated very sparsely, such that colonies would
be seeded from single cells (Figure 1B, part ii). Despite
these morphologic changes, preliminary experiments
showed no effect of MYB manipulation on monolayer
wound closure in either the MYB-transfected MDA-MB-
231 cells or sh-MYB-knocked-down LA cells (n = 1; data
not shown), and although a trend toward reduced Trans-
well migration was seen after MYB transfection of MDA-
MB-231 cells, this was not significant (n = 3; data not
shown). However, live cell-imaging analysis of monolayer
cells plated relatively sparsely revealed an altered morph-
ology and migration in the MYB-transfected MDA-MB-
231 cells, which grew mostly as connected, flatter cells
in epithelial groups compared with a carpet of smaller,
fibroblast-like, bipolar, and round cells in the control
cultures, and showed a slower, more-tortuous migration
pattern than the vector control cells over a 4-hour period
(see Additional file 7). In the 9-day EGF-EMT treatment
regimen used previously, MYB knockdown appeared fur-
ther to enhance the repression of CDH1 (see Additional
file 8A, n = 1). In MYB-overexpressing MCF-7 cells,
the epithelial phenotype was enhanced, as evidenced by
significant reductions in VIM and SNAI1 expression
(Additional file 8B).Potential reciprocal repression of ZEB1 by MYB
QRT-PCR analyses of the MYBsh-LA cells revealed an
upregulation of ZEB1 expression in variant 2 (Figure 6(i)),
the variant with the best MYB knockdown (Figure 1A,
part i), suggesting that MYB represses ZEB1 expression in
PMC42-LA. Similarly, ZEB1 was significantly repressed in
MYB-transfected MDA-MB-231 cells (Figure 6(ii)), des-
pite no detectable change in CDH1 expression (data
not shown).
Figure 5 MYB and ZEB1 expression are inversely correlated in various in vivo and in vitro biologic settings. (A) MYB expression is
reduced in EMT. (i) Exposure of MDA-MB-468 cells to hypoxia (1% oxygen) for up to 5 days led to significant (*P < 0.05, repeated measures
one-way ANOVA with Dunnet multiple comparison test) induction of the hypoxia-indicator gene carbonic anhydrase 9 (CAIX) and significant
EMT-related gene changes, including the induction of ZEB1 and repression of MYB. (ii) Treatment of PMC42-LA cells with 10 ng/ml EGF for 9 days
(EGF-containing media replenished every 3 days) induced an EMT in which ZEB1 expression was significantly (*P < 0.05, Student paired t test)
induced and MYB repressed. For both (i) and (ii), results shown are QRT-PCR data, expressed as fold change (corrected to untreated cells), of three
independent experiments, and error bars represent SEM. Morphologic changes of MDA-MB-468 cells exposed to hypoxia and EGF-treated
PMC42-LA are found in Additional file 5A and B, respectively. Further evidence of MYB-expression reduction in EMT is found in Additional file 6A
and B. (B) Plot of expression of MYB across various breast tumors of increasing aggressiveness, using data derived from a publically available
microarray dataset [50]. (C) MYB tumoral staining correlates with CDH1 and inversely correlates with VIM in (i) matched human breast tumor
primary (Primary T) and sentinel lymph node metastases (LN MET); and in (ii) nonrelated human breast cancer bone metastases. Magnification
400×; scale bar, 150 μm. Findings further supported by IHC shown in Additional file 5D.
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Figure 6 Potential reciprocal repression of ZEB1 by MYB. (i) A trend for ZEB1 upregulation was observed in MT-PCR analysis of mesenchymal
gene expression in MYBsh-LA variants 1 and 2. (ii) ZEB1 was significantly downregulated in MYB-overexpressing MDA-MB-231. QRT-PCR
expression analyses showing fold change (vector control set to 1); n = 3, error bars represent SEM. Significance is indicated by the asterisk,
where P < 0.05. (Student paired t test used).
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These experiments indicated that MYB and ZEB1 are
inversely expressed in LA versus ET cells and in MDA-
MB-231. We therefore reasoned that ZEB1 might directly
repress MYB by binding to Z- or E-box consensus se-
quences within MYB. We identified four sequences within
MYB that conformed to either the Z- or E-box consensus
[4,5] (indicated as Z-box 1, E-box 1, E-box 2, and Z-box 2;
Figure 2A part i and Figure 2B). Z-box 1 (ACAGGTAA)
encompassed nt position +219 to +266, such that this
sequence spanned the MYB exon 1 and intron 1 junction
(Figure 2A, part I, and Figure 2B). E-box 1 (GCAGGTGG)
encompassed nt position +294 to +301 and was posi-
tioned within intron 1 (Figure 2A, part I, and Figure 2B).
E-box 2 (CCAGGTGC) encompassed nt position +550
to +558 and was positioned within intron 1 (Figure 2A,
part I, and Figure 2B). Z-box 2 (GCAGGTAG) encom-
passed nt position +687 to +694 and was also positioned
within intron 1 (Figure 2A, part i, and Figure 2B). Each of
the Z- and E-box sites was conserved between human,
mouse, and dog DNA sequences (Additional file 9A).
We next examined via a CAT reporter-gene assay
whether ZEB1 has a direct functional effect on the MYB
via the region containing Z-box 1, E-box 1, E-box 2 and
Z-box 2 (Figure 2A, parts i and iii) . In this assay, we co-
transfected an MYB promoter-intron 1-CAT construct
containing Z-box 1, E-box 1, E-box 2, and Z-box 2 with
a ZEB1 expression vector (pcDNA3.1-ZEB1) into HEK
293 cells and assessed CAT reporter activity (Figure 2A,
parts i and iii). Protein expression from the ZEB1 con-
struct was confirmed by Western blot (Figure 2A, part ii).
CAT reporter-gene assays showed that the expression of
exogenous ZEB1 in HEK 293 cells repressed the activity of
the MYB promoter-intron 1-CAT reporter (Figure 2A,part iii). These data suggest that ZEB1 can negatively
regulate MYB. This finding is consistent with the previous
observations that have shown that ZEB1 acts as a repres-
sor of gene activity [8-10].
To determine whether the Z-box 1, E-box 1, E-box 2,
and Z-box 2 sequences contributed to the ZEB1-
mediated repression of CAT activity, we next assessed a
series of CAT-reporter constructs in which the Z- and
E-box sequences were removed or mutated (MYB prom+
intron 1 CATb, deletes E-box 2 and Z-box 2; MYB prom
CAT, deletes E-box 1; MYB prom MUT CAT, mutates Z-
box 1). CAT reporter-gene assays showed that ZEB1
repressed the activity of all of the deletion and mutant
CAT reporter constructs including MYB prom MUT
CAT (Figure 2A, parts i and iii). The MYB gene can posi-
tively autoregulate itself via sites in its proximal promoter
[54]. Co-transfection of an MYB expression vector with
MYB prom MUT CAT confirmed the activity of this
reporter.
Collectively these data suggest that, in the context of
the CAT reporter construct, the repressive activity of
ZEB1 in HEK 293 cells was not dependent on the pres-
ence of the Z-box 1, E-box 1, E-box 2, or Z-box 2. We
did not observe additional Z- or E-box consensus sites
within the MYB promoter, exon1, or intron 1. This
suggests that ZEB regulation of MYB may occur via
ZEB1 binding to alternative nonconsensus site(s) within
intron 1 or via alternative upstream sequences within
exon 1 or the MYB promoter.
We next examined whether endogenous ZEB1 directly
bound MYB in vivo by chromatin immunoprecipitation
(ChIP) analysis. We undertook ChIP of SCRsh-ET and
ZEB1sh-ET cells with an antibody directed against
ZEB1, and experiments were performed at a standard
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QPCR analysis of the immunoprecipitated chromatin used
an optimized primer pair located at the 5′ end of in-
tron 1 (Figure 2B). This approach allowed the analysis
of ZEB1 occupancy of MYB across the region encom-
passing the 5′ end of intron 1 and the downstream prox-
imal promoter and exon 1 (Figure 2B). ChIP data in
Figure 2C suggest that in SCRsh-ET cells, MYB was
enriched for ZEB1 binding. In contrast in ZEB1sh-ET
cells, in which ZEB protein expression was decreased
(shown by Western blot in Figure 4A, part i), ZEB1 bind-
ing was reduced (Figure 2C). Additional repeats of this
experiment are shown in Additional file 9B. These
data suggest that endogenous ZEB1 directly bound
MYB in vivo in a region encompassing the 5′ end of
intron 1 and the flanking proximal promoter and exon 1.
Collectively, the CAT reporter and ChIP analyses sug-
gest that MYB is a target of ZEB1 and that ZEB1 exerts
its repressive activity via nonconsensus sites located
within the region spanning the 5′ end of intron 1 and
the flanking proximal promoter of MYB.
Discussion
Breast cancer metastases in soft tissue and bone have
been reported to reexpress CDH1 [55,56]. We have pro-
posed that the restoration of proliferation required for a
secondary tumor to form may be linked to the reversion
of EMT, or MET, and we suggest that MYB plays a
central role here in promoting tumor growth and the
epithelial phenotype. Furthermore, we have established a
functional and reciprocal relation between ZEB1 and
MYB that is prevalent in breast cancer systems. Direct
repression of MYB by the EMT driver ZEB1 builds ontoFigure 7 Schematic depiction of the regulation of MYB expression, an
various metastatic stages (detailed on the X-axis). Hypoxia/EGF positio
signals by these factors. This may lead to the induction of a cascade of CD
the mesenchymal phenotype, resulting in further protection from immune
indolent tumor cells may circulate and/or remain disseminated until a suita
factors, such as hormone fluctuations associated with age and/or pregnanc
created, triggering the reexpression of MYB, which may in turn repress ZEB1.
actively grows until the cycle is repeated.the paradigm through which tumor growth, invasion,
and metastasis are integrated (Figure 7). Resistance to
apoptosis [57], reduced proliferation [5,58], and tumor
dormancy [59,60] have all been associated with EMT in
the past, but the potential role of MYB in this process
is novel.
Examining the consequences of MYB knockdown in
LA cells (Figure 1A), and the overexpression of MYB
expression in MDA-MB-231 cells (Figure 1B) and MCF-7
cells (see Additional file 8B) has shown (a) that the
manipulation of MYB expression has a direct consequence
on epithelial versus mesenchymal state, and (b) MYB
expression is concordant with the epithelial phenotype in
terms of marker expression, culture and colony morph-
ology, and random migration in the monolayer. We have
also found increased MYB expression on CDH1 knock-
down in MDA-MB-468 cells (not shown).
How could MYB expression determine epithelial state?
One possibility that we have considered is through
promotion of KLF4 expression. KLF4 was noted as a
novel gene upregulated by MYB via occupation of the
KLF4 promoter in MCF-7 cells treated with estradiol
[61]. KLF4 is a metastasis-suppressor gene that drives
CDH1 expression, preventing EMT [62]. Thus in an
actively growing, ER-positive primary tumor, MYB may
transduce estrogen signaling into both proliferation [16]
and promotion of the epithelial phenotype. Further stud-
ies will be needed to determine whether this MYB-KLF4
partnership occurs in secondary tumors, whether this
may be a means through which MYB could mediate
the restoration of CDH1 at these sites, and the func-
tional importance of the epithelial aspect regulated
by MYB.d hence proliferative rate (represented on the Y-axis) by ZEB1 at
ned at the apex of each MYB curve indicates the switching on of EMT
H1-repressor genes, resulting in ZEB1 induction, which acts to stabilize
-derived apoptotic signals within the bloodstream. Thus, these clinically
ble, perhaps normoxic, secondary niche is found. Combined with other
y or inflammation, a more conducive tumor microenvironment is
The net result is the reversion of EMT (MET), and the secondary tumor
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ZEB1 and hence relieve ZEB1-mediated CDH1 tran-
scriptional repression, restoring the epithelial phenotype.
This is suggested by the upregulation of ZEB1 on the
knockdown of MYB in LA cells (Figure 6(i)) and the
repression of ZEB1 in MYB-overexpressing MDA-MB-
231 cells (Figure 6(ii)), and also by previous work in
hematopoietic cells [19]. A predicted MYB binding site
was identified in intron 1 of ZEB1, the site which is
mutated in mice with multiple developmental malfor-
mations, some of which were suggested to be related to
dysfunctional EMT or MET [20]. Thus, similar to the
ZEB1-miR200 reciprocal regulatory relation [4], our data
suggest a mutually antagonistic negative-feedback loop
between ZEB1 and MYB. ZEB1 and MYB may therefore
act as biologic switches, translating molecular changes
in the tumor microenvironment into alterations in cell
state. These may be epithelial or mesenchymal, as
illustrated in Figure 7.
We have shown that ZEB1 binds to the MYB gene in a
region encompassing the promoter and intron 1 (Figure 2B).
Furthermore, CAT-reporter experiments suggest that the
overexpression of ZEB1 represses MYB promoter-intron 1
activity (Figure 2C). This finding is supported by ET-LA
cell comparative studies (Figure 3), the characterization
of ZEB1sh-ET cells (Figure 4), and a potential role in
the EMT of MDA-MB-468 (hypoxia) and LA cells
(EGF) (Figure 5A), leading us to conclude that ZEB1
directly targets and represses MYB. Our deletion-mapping
studies suggest that ZEB1 can operate through alternative
regions, such as the MYB promoter. Although we did not
identify exact consensus binding sites for ZEB1 within the
promoter, this suggests that ZEB1 may work through
divergent binding sites or indirectly by impinging on the
activity of a transactivator, such as MYB. Given that MYB
is a gene that positively autoregulates itself via tandem
MYB binding sites located in the proximal promoter
region [54], and that ZEB1 has been shown to inhibit
the transcriptional activity of MYB [19], we propose
that ZEB1 represses MYB gene expression by inter-
cepting the positive-feedback cycle of MYB. ZEB1
downregulates miR34a in a similar manner by directly
repressing the miR34a-positive transactivating protein,
ΔNp63, resulting in the acquisition of invasive tumor
cell capabilities [63].
Likewise, our studies outline the consequences of
ZEB1-mediated gene repression, that is, the suppression
of epithelial gene expression and cellular proliferation in
breast cancer cells.
The role of MYB in EMT is controversial, and most
likely is context dependent. MYB has been positively im-
plicated in the induction of an EMT of avian embryonic
neural crest cells [64] and recently in the induction of
Snail2 expression in EMT of embryonic kidney, coloncarcinoma, chronic myeloid leukemia-blast crisis, and
neuroblastoma cells [65]. Knopfova et al. [66] recently
showed increased migration and Matrigel invasion, but
not collagen invasion, in MYB-transfected-MDA-MB-
231 cells, which contrasts our live-cell imaging results
for random monolayer migration. In further contrast to
our results, it has been shown that TGF-β-induced EMT
of ER-positive breast cancer cells is dependent on MYB
upregulation, in which putative miR-200 family binding
sites were identified in the MYB mRNA, and the
downregulation of these miRs was pinpointed as the
mechanism driving this EMT [67]. We have observed
a significantly higher level of expression of miR-200 family
in LA cells compared with ET (unpublished observation),
but increased MYB expression in the LA cells that overex-
press all miR-200 family members. In addition, in MYB-
overexpressing MCF-7 or MDA-MB-231 cells, we did not
observe an induction of Snail2 (Additional file 8B, C) nor
did we find any association between MYB induction and
EMT, but found the opposite (Figure 5A; Additional file
6A, B). We also found no association between MYB and
Snail2 in Luminal versus Basal breast cancer subtypes (see
Additional file 10). These dramatic differences could be
due to cellular context, because much of our work was
performed in the PMC42 model system, which clusters
with Basal A/Basal breast cancer cell lines (T. Blick, E.
Tomascovic-Crook, unpublished data). However, our re-
sults were supported by similar findings in luminal, ER+
breast cancer cells such as MCF-7 and T47D. It seems
more likely that our findings are specific to ZEB1, which
we find to be expressed later during the EMT, after SNAI1
and 2 induction in the EGF and EGF/staurosporine-in-
duced EMT in our system [39]. Of the CDH1 repressor
genes, ZEB1 has been found by others to be the more-
dominant EMT driver, important in stabilizing and main-
taining the mesenchymal phenotype in breast cancer
systems [5,9,68]. It is possible that MYB contributes to
early EMT responses by driving Snail 1 and 2 expression
while repressing ZEB1, until stronger driving forces acti-
vate ZEB1, suppress MYB, and thus suppress SNAI1 and
2. Further work is required to delineate these poten-
tially distinct EMT states and the capricious role that
MYB may play.
Comparison of the EMT gene-expression profiles in con-
trol versus ZEB1 knockdown PMC42-ET cells (Figure 4A,
part iii) may provide insights into specific gene-expression
changes that may occur during MET at the secondary
tumor site. For example, PAX6 was significantly upregu-
lated in ZEB1sh-ET cells. PAX6 has been described as a
tumor suppressor, suppressing invasiveness of glioblast-
oma cells and MMP2 expression [69], both of which are
hallmarks of EMT [6]. PAX6 has also been implicated in
promoting the proliferation of breast cancer cells [70],
and we have reported that PAX6 is a direct MYB target
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upregulation of PAX6 may also have contributed to the
enhanced proliferative rate observed for ZEB1sh-ET.
CDH5 expression was significantly downregulated in
ZEB1sh-ET cells (Figure 4A, iii). CDH5 has been shown to
be induced in an EMT of mammary tumor cells, influen-
cing the levels of Smad2 phosphorylation and upregulat-
ing the expression of TGF-β target genes [72]. CD24 was
found to be significantly increased in the ZEB1sh-ET cells,
correlating with increased CD24 receptor expression, as
determined by FACS (data not shown), consistent with
our previous findings that EMT traits in human breast
cancer cell lines correlate with the CD44(hi/+)/CD24(lo/-)
stem-cell signature [12,73]. MMP1 expression was sig-
nificantly reduced in the ZEB1sh-ET cells. Therefore,
the ZEB1sh-ET cells reexpress markers of the epithelial
phenotype.
Conclusions
We have shown that ZEB1 transcriptionally represses
MYB to achieve two outcomes: to downregulate cell
proliferation and to stabilize the mesenchymal pheno-
type. Both outcomes are likely to be beneficial to the
survival of the cancer cell in the systemic circulation and
at sites of dissemination. EMT has been linked to the
acquisition of cell dormancy and reduced chemothera-
peutic efficiency (reviewed in [74]). In addition, a sus-
tained mesenchymal state may enable escape from
immune-related apoptotic signals via expression of
factors such as SNAI1, which may act to suppress these
signals and the immune system itself [75]; reviewed in
[76]. An ongoing debate in relation to the treatment of
metastatic breast cancer is whether to customize therap-
ies that reactivate proliferation in dormant, circulating
tumor cells and hence improve chemotherapeutic effi-
ciency, or to maintain dormancy in these rogue cells
[77,78]. Each approach is equally problematic, but gene-
targeted modulation along the ZEB1-MYB axis may pro-
vide an avenue to tackle this foremost clinical dilemma.
Note added in proof
As we noted earlier, the Raschella group initially repor-
ted that MYB expression was upregulated in ER-positive
human breast cancer cell lines after TGF-β treatment
because of transcriptional activation, release of miR-200
family suppression, and protein stabilization, and was
instrumental in promoting EMT effects [67]. Since our
manuscript was submitted, the Raschella group pub-
lished a follow-up article [79] showing that MYB also
activates the expression of the miR-200 family, which
blocks ZEB1 expression. These new findings now sup-
port our key conclusion, that MYB favors the epithelial
rather than mesenchymal state and opposes EMT. The
authors also support our proposal of contextual issuessurrounding MYB regulation of EMT processes in re-
sponse to signals such as TGF-β, because in the combined
presence of MYB and ZEB1, the ZEB1 suppression of
miR200 is dominant. This may explain the discrepancies
seen in our PMC42 model system compared with their
original study. MYB seems poised for only transient
expression in the epithelial setting because of the MYB-
miR-200 feedback loop. The effects of TGF-β are also
known to be very much context dependent.Additional files
Additional file 1: (A) The expression (MT-PCR) of other EMT-related
genes in SCRsh-ET versus ZEB1sh-ET, not shown in Figure 4
(A, part iii). (B) Additional SRB experiments supporting the SRB data
shown in Figure 4C, part ii. (C) Clonogenic assay of SCRsh-ET versus
ZEB1sh-ET showing that ZEB1 knockdown led to larger overall colony
size, consistent with a higher rate of proliferation. Colony number and
size were averaged from thresholded images of six individual 10-cm-diameter
plates (n = 6) by using the Image J image-analysis program
(*P < 0.05; error bars represent SEM. Statistics were determined by
using Student paired t test).
Additional file 2: MYB-targeted knockdown in ZEB1sh-ET cells
abrogates the effect of ZEB1KD on colony size. (A) (i) Validation of
MYB knockdown in MYB shRNA expressing SCRsh-ET and ZEB1sh-ET cells
by QRT-PCR (fold expression relative to SCRsh-ET/SCRsh-ET shown, n = 1,
error bars represent SD) and (ii) Western blotting analysis. (B) clonogenicity
assay revealing ZEB1sh/MYBsh-ET cells form smaller colonies, indicating a
reduction in proliferative rate (n = 3 independent biologic replicates, error
bars represent SEM).
Additional file 3: (A) DAB immunocytochemistry staining of ZEB1sh-ET
shows reduced nuclear ZEB1, magnification 600×, scale bar, 100 μm; (B)
The EpCAM receptor was reexpressed in ZEB1sh-ET, as shown by (i) greater
retention to EpCAM coated beads (inferred by reduced number of unbound
cells in the flow-through population); and (ii) FACS for EpCAM. CDH1 pro-
tein reexpression shown in Figure 4A was further confirmed by FACS to be
membrane bound. The results from three independent experiments
(biologic replicates) are shown. (C) (i) Confocal microscopy of PMC42-ET
spheroids grown on Matrigel revealed CDH1 was expressed at the cell
membrane in ZEB1sh-ET, magnification 400×, scale bar, 30 μM; (ii) ZEB1sh-ET
spheroids were generally larger than SCRsh-ET, consistent with previous work
in MDA-MB-231, in which ZEB1 was knocked down [10]. PMC42-ET WT cell
organoids were not enlarged and were comparable in size to SCR shRNA-ET
control (not shown). 100× magnification; scale bar, 200 μM. (iii) ZEB1sh-ET
cells grew as tighter clusters in 2D culture (magnification 200×; scale bar,
50 μM) and exhibited slower epithelial-like movement in this dimension
(see Additional file 4). (D) MYB was expressed higher in ZEB1sh-ET cells,
regardless of the dimension of culture.
Additional file 4: PMC42 cells transfected with siRNA: scrambled (A)
or Zeb1 (B). Stills from movies at an interval of 3 hours are shown, and
paths of movement of seven cells in each field are projected in yellow
on the first time frame of each. Traces for PMC42ET-shSCR control
(147.3 ± 52.1 μm/4 hours) and PMC42ET-shZeb1 cells (60.9 ±17.2 μm/4 hours;
P < 0.0001). Note that the more-epithelial appearance of the Zeb1 siRNA-
transfected cells correlates with very short paths. Tracking point was the
center of the cell nucleus.
Additional file 5: (A) Immunofluorescence of MDA-MB-468 cells seeded
in Terasaki plates exposed to hypoxic conditions (1% O2) for various
times, as indicated. CDH1 sublocalization to the cytoplasm from the
membrane was seen, along with an increase in the expression of VIM
protein in a time-dependent manner on exposure to hypoxia; magnification
600×; scale bar, 50 μm. (B) Phase-contrast images of untreated or 10 ng/ml
EGF-treated PMC42-LA, depicting the acquisition of mesenchymal features:
scattering and an elongation of cell shape, magnification 100×; scale bar,
200 μM. (C) Comparison of expression levels of MYB, ZEB1, and CDH1 in
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the Neve dataset [13]. Significance (*) set at P < 0.05, Mann–Whitney statistical
test. (D) An additional matched human breast tumor primary (Primary T) and
sentinel lymph node metastases (LN MET) set to that shown in Figure 5;
magnification, 400×; scale bar, 150 μm.
Additional file 6: Additional cell models of EMT in which MYB was
repressed (A, B). (A) Expression (QRT-PCR) analyses of MCF-7 cells
exposed to hypoxia for up to 72 hours. (B) T47D cells treated for up to
120 hours with 10 ng/ml EGF.
Additional file 7: Representative images of the (A) vector control
and (B) MYB-transfected MDA-MB-231 cells under phase-contract
microscopy, showing tracking of path length over a 4–hour period.
For each, two groups of seven closely spaced cells were selected for
tracking. Tracking point was the center of the cell nucleus. Yellow
denotes representative 4-hour traces for MDA-MB-231-vector control
(147.7 ± 30.6 μm/4 hours; 4-hour displacement = 42% of path length,
that is, relatively straight) and MYB-transfected MDA-MB-231 cells
(91.2 ±19.01 μm/4 hours; 4-hour displacement = 25% of path length;
that is, quite tortuous).
Additional file 8: (A) Knockdown of MYB in PMC42-LA cells
(which were characterized in Figure 1) led to a further reduction
of CDH1 expression after induction of EMT by EGF. Data shown
are fold change, relative to untreated SCRsh-LA; n = 1, error bars represent
standard deviation. (B) Stable overexpression of MYB in MCF-7 cells
(i) validated by immunocytochemistry (DAB), magnification 100×, scale
bar, 200 μm; and (ii) fold changes in mesenchymal gene expression
compared with WT MCF-7. Data shown are an average of three
independent experiments; error bars represent SEM, significance (P < 0.05)
indicated by *, as determined by Student paired t test. (C) Stable MYB
overexpression in MDA-MB-231 cells does not result in Snail2 expression
upregulation: MT-PCR data expressed as fold change (Vector control
MDA-MB-231 = 1); n = 1; error bars represent standard deviation.
Additional file 9: (A) E and Z-boxes number1 within the MYB promoter
captured in the ChIP analysis are highly conserved between Homo
sapiens, Mus muscularis, and Canis familiaris, as are E and Z-boxes number
2 downstream. (B) Additional graphs/replications of ChIP analyses
summarized in Figure 2: QRT-PCR of two independent replications of
ChIP assay examining the region of the MYB promoter defined in Figure 1.
(C) QRT-PCR positive control for ChIP assay: amplification of the region of
the CDH1 promoter containing E-boxes at which ZEB1 has been demonstrated
to bind. (D) QRT-PCR negative control: amplification of a nonrelated
sequence within MYB gene in intron 10.
Additional file 10: An inverse correlation was observed between
Snail2 and MYB expression in Luminal versus BasalB subgroups
of human breast cancer cell lines from the Neve dataset [13].
Significance (*) set at P < 0.05, Mann–Whitney statistical test.Abbreviations
2D: Two dimensional; 3D: Three dimensional; ANOVA: Analysis of
variance; ATCC: American Type Culture Collection; bp: Base pair;
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immunoprecipitation; DAB: 3,3′-diaminobenzidine; DMEM: Dulbecco
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ICC: Immunocytochemistry; IF: Immunofluorescence;
IHC: Immunohistochemistry; LA: PMC42-LA cells; LN MET: Lymph node
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